Please use this identifier to cite or link to this item: https://doi.org/10.18632/oncotarget.16037
Title: Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients
Authors: Chan, T.S.-Y
Lee, Y.-S
Del Giudice, I
Marinelli, M
Ilari, C
Cafforio, L
Guarini, A
Tan, D
Phipps, C
Goh, Y.T 
Hwang, W 
Goh, A.Z.-K
Siu, L.L.-P
Wu, S
Ha, C.-Y
Lin, S.-Y
Kwok, C.-H
Lau, C.-K
Wong, K.-F
Foà, R
Kwong, Y.-L
Tse, E
Keywords: chlorambucil
cyclophosphamide
fludarabine
immunoglobulin heavy chain
myeloid differentiation factor 88
Notch1 receptor
rituximab
adult
advanced cancer
age
aged
Article
cancer staging
cancer survival
Chinese
chronic lymphatic leukemia
clinical feature
cohort analysis
controlled study
correlational study
early cancer
female
fluorescence in situ hybridization
follow up
gene sequence
human
IGHV gene
karyotyping
major clinical study
male
molecular pathology
monotherapy
MYD88 gene
NOTCH1 gene
overall survival
progression free survival
somatic mutation
time to treatment
treatment outcome
tumor suppressor gene
Issue Date: 2017
Publisher: Impact Journals LLC
Citation: Chan, T.S.-Y, Lee, Y.-S, Del Giudice, I, Marinelli, M, Ilari, C, Cafforio, L, Guarini, A, Tan, D, Phipps, C, Goh, Y.T, Hwang, W, Goh, A.Z.-K, Siu, L.L.-P, Wu, S, Ha, C.-Y, Lin, S.-Y, Kwok, C.-H, Lau, C.-K, Wong, K.-F, Foà, R, Kwong, Y.-L, Tse, E (2017). Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. Oncotarget 8 (15) : 25455-25468. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.16037
Rights: Attribution 4.0 International
Abstract: Chronic lymphocytic leukaemia (CLL) is uncommon in Chinese population and its biology, genetics and treatment outcome in Chinese patients have not been comprehensively investigated. In this study, we studied the clinicopathological features and outcome of 212 Chinese patients with newly diagnosed CLL in Hong Kong and Singapore. The median age at diagnosis was 64 years. The majority of patients presented with early-stage disease (Binet stage A, 56.1%). Del(13) (q14) was the most frequent abnormality (41.7%) detected by fluorescence in situ hybridization (FISH) analysis. Del(17p) and TP53 gene mutations were detected in 7.8% and 8.2% of patients, respectively. MYD88 mutations were found at a higher frequency (11.5%) than expected. CLL with unmutated variable region of the immunoglobulin heavy chain genes (IGHV) occurred in only 31.2% of cases, and was associated with advanced-stage disease (p < 0.01) and adverse FISH abnormalities (p < 0.01). With a median follow-up of 39 months, the median overall survival (OS) was 108 months. The presence of del(17p) or TP53 mutations was associated with a significantly shorter time to first treatment and an inferior OS (p < 0.01). Unmutated IGHV was also associated with a significantly shorter time to treatment (p < 0.01). Among patients who required treatment, the median OS and progression-free survival (PFS) were 107 and 23 months, respectively. The presence of del(17p) was associated with a significantly inferior OS and PFS (p < 0.01). In summary, Chinese CLL patients had similar genetic aberrations at diagnosis compared with those of Western populations. FISH abnormalities are major factors affecting outcome.
Source Title: Oncotarget
URI: https://scholarbank.nus.edu.sg/handle/10635/179763
ISSN: 1949-2553
DOI: 10.18632/oncotarget.16037
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_18632_oncotarget_16037.pdf2.74 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons